Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis

Xin Wang, Tatiana Nanovskaya, Ying Zhan, Susan M. Abdel-Rahman, Marlo Jasek, Gary Hankins, Mahmoud Ahmed

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective. The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Methods. Twenty patients received metronidazole (Flagyl®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4. Results. Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C max) and the area under the plasma concentration-versus-time curve (AUC 0-12), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose. Conclusions. The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.

Original languageEnglish (US)
Pages (from-to)444-448
Number of pages5
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume24
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Bacterial Vaginosis
Metronidazole
Pharmacokinetics
Pregnancy
Area Under Curve
Weights and Measures
Pharmaceutical Preparations

Keywords

  • Bacterial vaginosis
  • metronidazole
  • pharmacokinetics
  • pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. / Wang, Xin; Nanovskaya, Tatiana; Zhan, Ying; Abdel-Rahman, Susan M.; Jasek, Marlo; Hankins, Gary; Ahmed, Mahmoud.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 24, No. 3, 03.2011, p. 444-448.

Research output: Contribution to journalArticle

Wang, Xin ; Nanovskaya, Tatiana ; Zhan, Ying ; Abdel-Rahman, Susan M. ; Jasek, Marlo ; Hankins, Gary ; Ahmed, Mahmoud. / Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. In: Journal of Maternal-Fetal and Neonatal Medicine. 2011 ; Vol. 24, No. 3. pp. 444-448.
@article{fca93cc74a2945abb48b4c6720553ad7,
title = "Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis",
abstract = "Objective. The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Methods. Twenty patients received metronidazole (Flagyl{\circledR}, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4. Results. Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C max) and the area under the plasma concentration-versus-time curve (AUC 0-12), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose. Conclusions. The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.",
keywords = "Bacterial vaginosis, metronidazole, pharmacokinetics, pregnancy",
author = "Xin Wang and Tatiana Nanovskaya and Ying Zhan and Abdel-Rahman, {Susan M.} and Marlo Jasek and Gary Hankins and Mahmoud Ahmed",
year = "2011",
month = "3",
doi = "10.3109/14767058.2010.497573",
language = "English (US)",
volume = "24",
pages = "444--448",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis

AU - Wang, Xin

AU - Nanovskaya, Tatiana

AU - Zhan, Ying

AU - Abdel-Rahman, Susan M.

AU - Jasek, Marlo

AU - Hankins, Gary

AU - Ahmed, Mahmoud

PY - 2011/3

Y1 - 2011/3

N2 - Objective. The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Methods. Twenty patients received metronidazole (Flagyl®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4. Results. Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C max) and the area under the plasma concentration-versus-time curve (AUC 0-12), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose. Conclusions. The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.

AB - Objective. The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Methods. Twenty patients received metronidazole (Flagyl®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4. Results. Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C max) and the area under the plasma concentration-versus-time curve (AUC 0-12), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose. Conclusions. The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.

KW - Bacterial vaginosis

KW - metronidazole

KW - pharmacokinetics

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=79751484134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751484134&partnerID=8YFLogxK

U2 - 10.3109/14767058.2010.497573

DO - 10.3109/14767058.2010.497573

M3 - Article

C2 - 20608802

AN - SCOPUS:79751484134

VL - 24

SP - 444

EP - 448

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 3

ER -